Litchfield Hills Research Weighs in on Vyome FY2026 Earnings

Vyome Holdings, Inc. (NASDAQ:HIND) – Analysts at Litchfield Hills Research raised their FY2026 earnings per share (EPS) estimates for shares of Vyome in a research note issued on Tuesday, September 22nd. Litchfield Hills Research analyst T. O’neill now expects that the company will post earnings per share of ($0.52) for the year, up from their previous forecast of ($0.60).

A number of other research analysts have also recently weighed in on HIND. Chardan Capital started coverage on shares of Vyome in a research report on Thursday, September 3rd. They set a “buy” rating and a $3.50 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Vyome in a report on Wednesday, July 29th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.25.

Vyome Stock Performance

NASDAQ:HIND opened at $2.01 on Thursday. The firm has a market capitalization of $14.11 million, a PE ratio of -0.60 and a beta of 1.50. The stock’s fifty day moving average is $2.14 and its 200 day moving average is $2.18. Vyome has a fifty-two week low of $1.75 and a fifty-two week high of $6.56.

Vyome (NASDAQ:HIND) last announced its earnings results on Wednesday, August 12th. The company reported ($0.10) EPS for the quarter. The company had revenue of $0.27 million during the quarter. Vyome had a negative return on equity of 197.33% and a negative net margin of 3,024.84%.

About Vyome

Vyome Holdings, Inc is a biotechnology company focused on developing therapies for dermatological conditions. The company’s research programs target inflammatory and infectious skin diseases, including acne and other conditions associated with imbalanced skin microbiomes.

Vyome has developed topical drug candidates and proprietary approaches intended to selectively address disease-causing bacteria while preserving beneficial microorganisms on the skin. Its pipeline has included investigational treatments for acne and other dermatology indications, although product candidates remain subject to clinical development and regulatory review.

The company’s operations are centered on the development of prescription dermatology medicines for potential commercialization in the United States and other international markets.